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ABSTRACT 
The main objectives of present work was to design and evaluate pellets of Carvedilol in order to increase patient compliance and 
therapeutically benefits. The pellets were made by the sub-coating with sodium bicarbonate and hydroxyl propyl methyl cellulose 
which was utilized to keep the spheres in stomach for long time. Hence sodium bicarbonate and hydroxyl propyl methyl cellulose are 
the key ingredients of this dissertation work. In vitro release trials were evaluated in response to check release of drug from the drug 
coated spheres. The release pattern of batches T1 to T6 was observed to vary due to variation in the concentration of HPMC 5cps, 
low substituted HPC and PVP K30. The trials T1-T3 showed the slow drug release due to combination of PVP K30 with low 
substituted HPC and HPMC 5cps; while the formulation T4-T6 showed the good release behavior as compare to T1-T3. 
Keywords:  Carvedilol, Multiparculate, Pellets, TLC, HPLC. 
 
 Article Info: Received 13 Aug, 2017; Review Completed 29 Oct, 2017; Accepted 08 Nov, 2017; Available online 15 Nov, 2017 
Cite this article as: 
Kurnool AN, Jat RK, Narendra C Novel multiparticulate drug delivery system of carvedilol as antihypertensive 
drug, Journal of Drug Delivery and Therapeutics. 2017; 7(6):49-55 
DOI: http://dx.doi.org/10.22270/jddt.v7i6.1511  
*Address for Correspondence  
Abdul Nasir Kurnool, Institute of Pharmacy, Shri JJT University Jhujhunu Raj-313001, Tel.: 9481547932, E-mail address: 
nasirmpharma@gmail.com   
 
 
INTRODUCTION 
Carvedilol is antihypertensive drug used for mild to 
moderate hypertension. It is beta blocker with additional 
alpha 1 blocking activity. It is administer orally and is 
immediately absorb from GIT. Peak medication impacts 
occur in 90 min of single units. In single unit study, in 
subjects administering with 5 mg and 10 mg drug, the 
mean peak concentrations (Cmax) were 59 (range: 29-
112) and 121 (range: 58-271) ng/mL, respectively, 
occurs at a mean time (Tmax) of 1.6h for both strengths. 
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ethyl]-amino]- 2-propanol 
Multiparticulate drug shipping device (MDDS), have 
been extensively used for administering via oral path, it 
includes wide variety of smaller discrete subunits which 
has exceptional homes. It’s specifically primarily based 
on subunits like microspheres
1, 2
, granules, pellets, beads 
3, 4, 5
 minitab and spheroids. Such kind of subunits gives 
numerous advantages as evaluate to monolithic kind 
gadgets. In MDDS, active pharmaceutical substances are 
get divides into range of subunits, usually which has 
number of round units which have diameter of about 
0.052 mm to 1.98 mm. to make use of or to administer 
total dose these subunits to be compacted in capsules or 
get crammed right into a optimistic packs or well 
encapsulated 
6
.  
The composition including multicomponent MDDS is 
feasible as it famous numerous mode of movement, it 
shows synergistic or additive effect, minimizes man or 
woman’s doses and limit the facet results. Though its 
miles more luxurious as compare to single treatment 
options within the quick term, it minimizes treatment 
failure ratio, reduce charge of case fatality and drop in 
improvement of resistance for designing of recent 
devices in long time type therapy
7, 8
. 
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Various formulation parameters that play a crucial role 
in the successful formulation of drugs are aqueous 
solubility, stability at ambient temperature and humidity, 
photo stability, compatibility with solvent and excipients 
9
. 
Multiple unit dosage units are pharmaceutical 
compositions in that the lively substance is available as a 
spread of smaller independent multiple devices. To 
provide the recommended each day dose, these form of 
small units are get well stuffed into a normal sachet and 
compressed or encapsulated right into a strong dosage 
shape. A couple of units are discrete small debris which 
give the multiple unit kind system. Additionally they 
display range of benefits over single-unit kind systems 
due to of their very smaller length. A couple of gadgets 
are much less depending on gastric emptying, which 
ends up in minimal intra and inter -issue type variant in 
gastro-intestinal transit kind. They also uniformly 
disbursed and really minimum assume to reason nearby 
type irritation.  
There are a couple of justifications for designing a active 
substance as a multiple unit gadget for e.g., to improve 
disintegration type inside the belly, or to show provide a 
comfortable, fast disintegrating kind tablet which get 
dissolve in aqueous medium early to swallowing which 
also can useful resource compliance with elder 
volunteers and small Childs. Multiple unit device gives 
well reproducible pharmacokinetic sample than 
monolithically or conventional formulations. After 
process of disintegration which observes inside a very 
much less minutes even in seconds, the character 
subunits get bypass immediately via a GI tract. If those 
debris or units have diameter not >1.99 mm, they have 
potential to left the stomach in non-stop way, even 
though the pylorus is being closed. These results in 
much less inter and intra subject versions in 
bioavailability and plasma stages. The main objectives 
of present work was to design and evaluate pellets of 
Carvedilol in order to increase patient compliance and 
therapeutically benefits. 
MATERIALS AND METHODS 
The following materials were used for the experimental 
work done. 
 
Table 1: List of Chemicals used 
 
1. Preformulation Study 
1.1 Melting point determination: 
Drug substance melting point was checked by using 
capillary method. Observed value was compared with 
the reported value. 
1.2 Scanning of carvedilol tartrate in 0.01N HCl: 
The solution having 10g/ml of carvedilol tartrate in 
0.01N HCl was manufactured and scan over the 
wavelength range of 200 - 400 nm against 0.01N HCl as 
blank utilizing UV spectrophotometer. A plot of 
wavelength verses absorbance was recorded using UV 
spectrophotometer. 
1.3 Standard curve of Carvedilol in 0.01N HCl: 
A correct weighing quantity of carvedilol (10 mg) was 
dissolve in 100 ml of 0.01N HCl to give a stock solution 
(100 µg/ml). The stocks solution is used to investigate 
the λmax of carvedilol. The aliquots (0.2 - 2 ml) of the 
stock solution which further diluted to 10 ml to 
manufacture standard solutions which have 
concentrations of 2 - 20 g/ml. The absorbance of 
solvents was calculated at 294.5nm utilizing double 
beam UV-Visible spectrophotometer against 0.01N HCl 
as a blank. The plot of absorbances verses concentration 
(g/ml) was plotted and results were subjected for linear 
regression study in MS Excel. Curve shown in figure 1. 
1.4 Drug-Excipients interaction study: 
1.4.1 FTIR spectroscopy:
10
 
Infrared spectra-photometry is a useful analytical tool to 
check chemical interactive action in active substance 
and various ingredients utilized in composition. A 
sample (1 mg) was mixed and powdered with 10 mg dry 
powdered of KBr. The mixing of powder was bringing 
in a sample and the spectrums were determined by 
screening in wavelength range of 400-4000 cm
-1
 using 
FTIR spectrophotometer. The drugs IR spectrum was 
compared with physical mix of drug and polymers to 
found for such possible active substance-excipients 
interaction.
 
1.4.2 Differential Scanning Calorimetry (DSC): 
A DSC (Mettler Toledo, Greifensee, Switzerland) is 
equipped with an intra-cooler device and refrigerating 
S.N. Name of chemical Grade Manufacturer /  Distributor 
1 Carvedilol USP Aurobindo Pharma, Hyderabad 
2 HPMC E5LV USP/NF, EP,JP Signet Chemical Corporation, Mumbai 
3 Low substituted HPC E5LV USP/NF, JP Signet Chemical Corporation, Mumbai 
4 PEG 6000 LR Clariant chemicals India Ltd, India 
5 Sodium Lauryl Sulphate AR Signet Chemical Corporation, Mumbai 
6 PVP K 30 LR Signet Chemical Corporation, Mumbai 
7 Talc LR S.D. Fine Chemicals Ltd., Mumbai, India 
8 Isopropyl Alcohol AR Loba Chemie Pvt. Ltd., Mumbai, India. 
9 Sodium Bicarbonate AR Allied Overseas, Mumbai, India 
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system was utilized to analyze thermal characteristics of 
carvedilol. Active substance loaded pellets and eudragit 
coated pellet in the range of 35 to 300ºC. Indium 
standard were utilized to calibrate temperature of DSC. 
Nitrogen gas was purging at 50 ml/min and 100 ml/min 
via cooling unit. 
2 Preparation of the coated pellets
11
 
Fluidized bed processor is a method for the preparation 
of the coated pellets. In this method; a core material 
(sugar spheres) is coated with the drug substance 
following a secondary coating process in which the 
coating of gas forming agent and tertiary coating of 
modified release controlling polymer material is 
performed.
 
Table 2: Drug loading on sugar pellets 
 
 
3 Characterization of Drug Coated Pellets: 
3.1 Micromeritic Properties: 
The characteristics like angle of repose, bulk density, 
tapped density, hausner ratio of spheres were checked to 
evaluate the flowing characteristics of spheres. The 
angle of repose near to the 20 shows excellent flow and 
for Hausner’s ratio around 1 show good flow properties. 
12
 
3.2 Morphology of Drug loaded pellets (SEM):  
The morphology of non pareils was checked by SEM. 
The view of pellets showed a spherical structure with 
rough surface morphology (Figure 10).  
3.3 Drug content
13
: 
Content of active substance from sphere formulation 
was investigated; in that quantity of spheres equivalent 
to 6.25 mg of dose of active substance was measured 
and dissolve in 0.01 N HCl, it is sonicated for fifteen 
minutes to dissolve it completely and then made the 
solution of 14 ppm which is consider as a working level 
for the overall analysis. The absorbance was found at the 
294.5 nm by UV spectrophotometry. The drug content 
of Batches T1 to T6 is shown in Table 3.  
3.4 In vitro drug release studies: 
In-vitro release of carvedilol from pellet compositions 
was determined by USP apparatus II (Paddle method). 
The release medium was 500 ml 0.01N HCl solution at 
37±0.5°C and the rotating speed of the apparatus was set 
to 50 rpm for all compositions (pellets). At certain time 
intervals, 1 ml of sample was withdrawn and rapidly 
equal amount of fresh media (37±0.5°C) was changed. 
For determining of carvedilol quantity, the UV 
absorbance of samples were calculated at λmax=294.5 
nm by UV spectrophotometers and overall quantity of 
drug released was measured with cumulative percentage 
active substance release. Percentage cumulative release 
of drug from coated spheres (T1 – T6) was given in 
Figure 11. 
12
 
RESULTS AND DISCUSSION 
1. Preformulation Study: 
1.1. Melting point determination:  
The melting point of carvedilol was found 194-196°C 
which complies with the reported value. 
1.2. UV Spectrum of carvedilol tartrate in 0.01N 
HCl: 
UV spectrum of carvedilol tartrate in 0.01N HCl showed 
that the drug had a λmax of 294.5 nm that was similar as 
reported.
 
1.3. Standard curve of carvedilol tartrate: 
The standard plot of carvedilol tartrate in 0.01N HCl is 
shown in fig 11. The correlation coefficient obtained 
was 0.997 and equation of regression line was y = 
0.0375x+0.0038. The standard calibration data shows 
that the absorbance value increases linearly as the 
concentration increases. 
 
 
Figure 1:  Standard Curve of carvedilol tartrate in 
0.01N HCl.
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Sr. No. Ingredients (gms) T1 T2 T3 T4 T5 T6 
1 Sugar Pellets (25-30#) 50 50 50 50 50 50 
2 Carvedilol(API) USP 1.25 1.25 1.25 1.25 1.25 1.25 
3 HPMC E5LV USP 2 4 2 - 4 4 
4 Low substituted HPC E5LV 2 2 4 4 2 - 
5 PVP K30  LR 4 2 2 2 - 2 
6 Sodium Lauryl Sulphate AR 0.2 0.2 0.2 0.2 0.2 0.2 
7 Isopropyl alcohol AR 20 20 20 20 20 20 
8 Talc LR 1.00 1.25 1.50 1.75 2.00 1.75 
9 0.1N HCL 60 60 60 60 60 60 
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1.4. Drug-Excipients Interaction study: 
1.4.1 FTIR Spectroscopy 
. 
Figure 2: FTIR of Carvedilol 
 
Figure 3: FTIR of Drug: PVP K30 
 
Figure 4: FTIR of Drug: SLS 
 
Figure 5: FTIR of Drug: Eudragit NE 40D 
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Figure 6: FTIR of Drug: Sodium bicarbonate 
 
Figure 7: FTIR of Drug: HPMC 
 
Figure 8: FTIR of Final Optimum Formulation 
The FTIR spectra of drug carvedilol tartrate showed OH 
stretching (bonded) at 3541.63 cm
-1
, CH aliphatic 
stretching at 2911.99 cm
-1
 and C=O stretching at 
1634.38 cm
-1
. 
The HPMC showed OH stretching (bonded) at 3457.74 
cm
-1
 and CH aliphatic stretching at 2832.92 cm
-1
.  
Sodium bicarbonate showed OH stretching (bonded) at 
3457.74 cm
-1 
and N-H stretching of NH at 3541.63 cm
-1
. 
Eudragit NE 40D showed C-H stretching of aromatic 
ring at 3070.12 cm
-1 
and C=O stretching at 1644.98 cm
-1
.  
SLS showed OH stretching (bonded) at 3545.49cm
-1 ,
 
CH aliphatic stretching at 2915.84 cm
-1 
and C=O 
stretching at 1634.38 cm
-1 
The IR spectra of drug- excipients mixture shown that 
prominent peaks of the drug were un-affected or 
displayed from its original position. Thus no interaction 
was observe between the active substance and 
excipients. Hence drug-excipients compatibility was 
established. There was neither shift nor dis-appearance 
of properties peaks concludes that there is no any 
interaction in carvedilol and other ingredients used in the 
formulation development or no degradation in drug 
molecule. 
The FTIR spectra of active substance and the physical 
mixture with different ingredients confirmed no 
presence of the interaction between active substance and 
the other ingredients. It also assured that the grades of 
excipients used in formulation are compatible with 
carvedilol. 
On the basis of melting point and FTIR spectrum of drug 
it is observed that the procured carvedilol was pure and 
it was free from any type of degradation product or any 
type of impurities. 
1.4.2 Differential Scanning Calorimetry 
DSC study was conducted to check the identity and 
purity of the Carvedilol. 
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Figure 9: DSC of Carvedilol 
On the basis of melting point, DSC study and FTIR 
spectrum of drug it is observed that the procured 
carvedilol was pure and it was free from any type of 
degradation product or any type of impurities. 
2 Characterization of Drug Coated Pellets: 
2.1 Micromeritic Properties: 
The results obtained for micromeritic properties of drug 
loaded spheres are shown in Table 3. The angle of 
repose near to the 20 shows excellent flow and for 
hausner ratio around 1 show good flow properties
14, 15, 16
. 
The results obtained for micromeritic characteristics of 
active substance loaded pellets showed good to excellent 
flow behavior.   
 
Table 3: Micromeritic properties of drug loaded pellets 
Formulation Batches Bulk density* (gm/ml) Angle of repose* Hausner ratio* Drug content* (%) 
T1 0.813±0.124 23.54±0.325 1.04±0.254 98.59±0.24 
T2 0.798±0.247 18.37±0.412 1.07±0.264 96.74±0.15 
T3 0.853±0.217 21.09±0.428 1.05±0.213 97.15±0.31 
T4 0.809±0.301 20.17±0.364 1.03±0.398 102.53±0.31 
T5 0.782±0.103 23.93±0.256 1.05±0.512 100.39±0.14 
T6 0.793±0.264 24.15±0.259 1.06±0.368 98.74±0.30 
*MeanS.D. (n=3) 
2.2 Morphology:  
The morphology of non pareils was checked by SEM. 
The view of pellets showed a spherical structure with 
rough surface morphology (Figure 10). After coating 
of non pareils, smooth surface of pellets was observed. 
SEM study at X100 as well as X60 magnifications 
revealed that the active substance layered spheres are 
dense with wrinkled, rough and porous circumference 
which is due to gradual loss of aqueous material during 
active substance layering process from the surface of 
spheres.  
2.3 Drug content 
The drug content of Batches T1 to T6 is shown in 
Table 3. The active substance content of drug loaded 
pellets was find to be 96.00 % -105 % for T1 –T6 
which was within the limits (Std. limits- 95% - 105%)
8, 
15
 
 
  
Figure 10: SEM photograph of drug loaded pellets
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2.4 In vitro drug release studies: 
 
Figure 11: Drug release of drug loaded pellets 
The release pattern of the drug loaded pellets is given in 
Figure 11. In vitro release trials were performed to check 
the release of active substance from drug coated spheres. 
The releasing profile of batches T1 to T6 was noted to vary 
due to changes in the quantity of HPMC 5 Cps, lower 
substituted HPC and PVP K30. The batches T1-T3 gives 
the minimum active material release due to combination of 
PVP K30 with lower substituted HPC and HPMC 5 cps; 
while the composition T4-T6 gives the better release 
pattern as compare to T1-T3. From the figure 11, it was 
shown that, the combination of low substituted HPC, 
HPMC 5cps and PVP K30 lowers the active substance 
release while combination of PVP K30 either with lower 
substituted HPC or HPMC 5cps gives better active 
substance release. Based on active substance release 
pattern, the composition T6 was chosen for further sub-
coating batches.  
CONCLUSION: 
The layering stage includes depositing of successive 
layering of active entities from suspension or solution on 
nuclei (pellets of inert material/sugar spheres). Solution 
layering includes depositing of respective layers of 
solutions of active materials on pellets. As the solution was 
sprayed onto the product bed, the droplets come in contact 
with cores and spread over surface evenly, shown that fluid 
dynamics and drying stages are favorable. This is following 
the drying stage which permits crystallizing dissolving 
substances and forming solid bridge in core and primary 
layer of active substance and between successive layers of 
active substance. This process continues until appropriate 
layers of active substance and hence target potency of 
spheres is achieved. A solution consists of polymer which 
used to increase the binding efficiency of drug substance. 
Polyvinyl pyrrolidone was used as a binding agent. Talc 
was used as glidant, antiadherants or antisticking agent. 
Sodium lauryl sulphate acts as a wet former. 
In vitro release trials were evaluated in response to check 
release of drug from the drug coated spheres. The release 
pattern of batches T1 to T6 was observed to vary due to 
variation in the concentration of HPMC 5cps, low 
substituted HPC and PVP K30. The trials T1-T3 showed 
the slow drug release due to combination of PVP K30 with 
low substituted HPC and HPMC 5cps; while the 
formulation T4-T6 showed the good release behavior as 
compare to T1-T3. From the figure 11 it was found that, the 
combination of HPMC 5cps, low substituted HPC and PVP 
K30 decreases the drug release while combination of PVP 
K30 either with low substituted HPC or HPMC 5cps shows 
better drug release. Based on drug release study, the 
formulation T6 was selected for further sub-coating trials.   
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